Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 7/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 3/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL622419 | 1.00 | BTK (0.51) | BTKDRD2KDM1AMAOBEPHX1 | |
| SCHEMBL697088 | 1.00 | BTK (0.51) | BTKDRD2KDM1AMAOBEPHX1 | |
| SCHEMBL6643451 | 0.91 | BTK (0.56) | BTKDRD2KDM1AMAOBEPHX1 | |
| SCHEMBL16856527 | 0.91 | BTK (0.56) | BTKDRD2KDM1AMAOBEPHX1 | |
| SCHEMBL3900948 | 0.91 | BTK (0.56) | BTKDRD2KDM1AMAOBEPHX1 | |
| SCHEMBL28480020 | 0.87 | DRD2 (0.48) | BTKDRD2KDM1AMAOBEPHX1 | |
| SCHEMBL30942791 | 0.87 | DRD2 (0.48) | BTKDRD2KDM1AMAOBEPHX1 | |
| SCHEMBL1067922 | 0.86 | BTK (0.50) | BTKDRD2KDM1AMAOBEPHX1 | |
| SCHEMBL13202379 | 0.86 | DRD2 (0.47) | BTKDRD2KDM1AMAOBEPHX1 | |
| SCHEMBL946942 | 0.86 | BTK (0.50) | BTKDRD2KDM1AMAOBEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236632-A1 | BETA-LACTAMASE INHIBITORS | VENATORX PHARMACEUTICALS INC (US) | 2025-07-24 | — | — | US | disclosed |
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-08-03 | — | — | US | disclosed |
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-08-03 | — | — | US | disclosed |
| WO-2023018236-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023017446-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
| WO-2021129584-A1 | PD-L1 ANTAGONIST COMPOUND | 杭州阿诺生物医药科技有限公司 | 2021-07-01 | — | — | WO | disclosed |
| EP-2928898-B1 | BETA-LACTAMASE INHIBITORS | VENATORX PHARMACEUTICALS INC (US) | 2021-04-14 | — | — | EP | disclosed |
| US-10669290-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190225628-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-07-25 | — | — | US | disclosed |
| US-20180194783-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. | 2018-07-12 | — | — | US | disclosed |
| WO-2014089365-A1 | BETA-LACTAMASE INHIBITORS | VENATORX PHARMACEUTICALS, INC (US) | 2014-06-12 | — | — | WO | disclosed |
| WO-2014089571-A1 | ANTICANCER COMPOUNDS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2014-06-12 | — | — | WO | disclosed |
| US-20110178098-A1 | ANTICANCER COMPOUNDS AND METHODS OF MAKING AND USING SAME | ST. JUDE CHILDREN'S RESEARCH HOSPITAL | 2011-07-21 | — | — | US | disclosed |
| US-20110178098-A1 | ANTICANCER COMPOUNDS AND METHODS OF MAKING AND USING SAME | ST. JUDE CHILDREN'S RESEARCH HOSPITAL | 2011-07-21 | — | — | US | disclosed |
| EP-2307377-A1 | NICOTINAMIDE DERIVATIVES | Pfizer Limited (GB) | 2011-04-13 | — | — | EP | disclosed |
| US-7767854-B2 | N-substituted phenylacetamide derivative and pharmaceutical composition containing the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-08-03 | — | — | US | disclosed |
| US-20100173888-A1 | Nicotinamide Derivatives | PFIZER INC | 2010-07-08 | — | — | US | disclosed |
| WO-2009155606-A1 | ANTICANCER COMPOUNDS AND METHODS OF MAKING AND USING SAME | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009153720-A1 | NICOTINAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2009-12-23 | — | — | WO | disclosed |
| US-20090082463-A1 | N-substituted phenylacetamide derivative and pharmaceutical composition containing the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194783-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | BTK 524/4885DRD2 3783/4885KDM1A 447/4885 |
| US-20250236632-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | BTK 524/4885DRD2 3783/4885KDM1A 447/4885 |
| US-20190225628-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | BTK 524/4885DRD2 3783/4885KDM1A 447/4885 |
| US-10669290-B2 | Beta-lactamase inhibitors | MGAM, GAA, LCT | BTK 524/4885DRD2 3783/4885KDM1A 447/4885 |
| US-20090082463-A1 | N-substituted phenylacetamide derivative and pharmaceutical composition containing the same | HRH4, HRH2, CNR2 | BTK 2590/4885DRD2 1323/4885KDM1A 1677/4885 |
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | BTK 2881/4885DRD2 4476/4885KDM1A 1866/4885 |
| US-20100173888-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | BTK 3009/4885DRD2 2161/4885KDM1A 2951/4885 |
| US-20110178098-A1 | ANTICANCER COMPOUNDS AND METHODS OF MAKING AND USING SAME | MKI67, MCL1, BAD | BTK 2809/4885DRD2 3942/4885KDM1A 2600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.